Show simple item record

dc.contributor.authorCortes, J. E.
dc.contributor.authorHochhaus, A.
dc.contributor.authorle Coutre, P. D.
dc.contributor.authorRosti, G.
dc.contributor.authorPinilla-Ibarz, J.
dc.contributor.authorJabbour, E.
dc.contributor.authorGillis, K.
dc.contributor.authorWoodman, R. C.
dc.contributor.authorBlakesley, R. E.
dc.contributor.authorGiles, F. J.
dc.contributor.authorKantarjian, H. M.
dc.contributor.authorBaccarani, M.
dc.date.accessioned2018-09-20T16:04:10Z
dc.date.available2018-09-20T16:04:10Z
dc.date.issued2011-04-05
dc.identifier.citationCortes, J. E. Hochhaus, A.; le Coutre, P. D.; Rosti, G.; Pinilla-Ibarz, J.; Jabbour, E.; Gillis, K.; Woodman, R. C.; Blakesley, R. E.; Giles, F. J.; Kantarjian, H. M.; Baccarani, M. (2011). Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117 (21), 5600-5606
dc.identifier.issn0006-4971,1528-0020
dc.identifier.urihttp://hdl.handle.net/10379/10921
dc.description.abstractNilotinib has significant efficacy in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and in patients with CML-CP or CML in accelerated phase (CML-AP) after imatinib failure. We investigated the occurrence of cross-intolerance to nilotinib in imatinib-intolerant patients with CML. Only 1/75 (1%) patients with nonhematologic imatinib intolerance experienced a similar grade 3/4 adverse event (AE), and 3/75 (4%) experienced a similar persistent grade 2 nonhematologic AE on nilotinib. Only 7/40 (18%) patients with hematologic imatinib intolerance discontinued nilotinib, all because of grade 3/4 thrombocytopenia. Ninety percent of imatinib-intolerant patients with CML-CP who did not have complete hematologic response (CHR) at baseline (n = 52) achieved CHR on nilotinib. Nilotinib induced a major cytogenetic response in 66% and 41% of patients with imatinib-intolerant CML-CP and CML-AP (complete cytogenetic response in 51% and 30%), respectively. Minimal cross-intolerance was confirmed in patients with imatinib-intolerant CML. The favorable tolerability of nilotinib in patients with imatinib intolerance leads to alleviation of AE-related symptoms and significant and durable responses. In addition to its established clinical benefit in patients with newly diagnosed CML and those resistant to imatinib, nilotinib is effective and well-tolerated for long-term use in patients with imatinib intolerance. This study is registered at http://www.clinicaltrials.gov as NCT00471497 (Blood. 2011; 117(21): 5600-5606)
dc.publisherAmerican Society of Hematology
dc.relation.ispartofBlood
dc.subjectabl tyrosine kinase
dc.subjectchronic myelogenous leukemia
dc.subjectbcr-abl
dc.subjectinhibitor nilotinib
dc.subjectformerly amn107
dc.subjectpdgf receptors
dc.subjectresistance
dc.subjectgrowth
dc.titleMinimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
dc.typeArticle
dc.identifier.doi10.1182/blood-2010-11-318949
dc.local.publishedsourcehttp://www.bloodjournal.org/content/bloodjournal/117/21/5600.full.pdf
nui.item.downloads0


Files in this item

This item appears in the following Collection(s)

Show simple item record